Meta-Analysis
Copyright ©The Author(s) 2022.
World J Meta-Anal. Aug 28, 2022; 10(4): 220-237
Published online Aug 28, 2022. doi: 10.13105/wjma.v10.i4.220
Table 1 Summary of patient characteristics of included randomised controlled trials and cohort studies
Ref.
Design
Country
Year
Arms
NP
Age/yr
% males
NL
Tumour size, mean or median (range or SD)/mm
CPC (A/B/C)
F/U Duration/mo
Abdelaziz et al[72], 2014RCTEgypt2009-2011MWA6653.6 (48.6-58.6)72.77629 (19.3-38.7)25/41/0NR
RFA4556.8 (49.5-64.1)68.95229.5 (19.2-39.8)24/21/0
Chong et al[34], 2020RCTHong Kong2011-2017MWA4763 (50–80)63.8NR31 (20–45)39/7/138.3 (2.3–78.0)
RFA4664.5 (42–5)82.628 (20–55)40/6/033.9 (4.9–72.7)
Kamal et al[35], 2019RCTEgypt2017MWA2855 (42-80)753432.5 (23.3-41.7)22/6/012
RFA2855 (42-80)78.63432.8 (23.7-41.9)22/6/012
Qian et al[36], 2012RCTChina2009-2010MWA2252 (43–75)90.92221 (17-25)22/0/05.1 ± 1.3 (2.8-6.5)
RFA2056 (43–76)952020 (15-25)20/0/05.1 ± 1.3 (2.8-6.5)
Shibata et al[23], 2002RCTJapan1999-2000MWA3662.5 (52–74)66.74622 (9–34)19/17/018 (6-27)
RFA3663.6 (44–83)72.74823 (10–37)21/15/018 (6-27)
Tian et al[37], 2014RCTChina2014MWA120NRNR8626 (13-39) NRNR
RFA7922 (13-31)
Vietti et al[38], 2018RCTFrance & Switzerland2011-2015MWA76NRNR98NRNR26 (18-29)
RFA7610425 (18-34)
Yu et al[22], 2017RCTChina2008-2015MWA203NRNR26527 (7– 50)NR35.2 (2.0–81.9)
RFA20025126 (9–50)35.2 (2.0–81.9)
Abdel-Samiee et al[33], 2020RetroEgypt2020MWA50NRNRNRNRNR36
RFA5036
Bouda et al[39], 2020RetroFrance2008-2016MWA7962.8 (52.4-73.2)819921.3 (13-29.6)71/8/034 (3–65)
RFA4362.2 (50.3-74.1)76.75223.0 (14.9-31.1)39/4/040 (5–126)
Chinnaratha et al[40], 2014RetroAustralia2006-2012MWA10162.1 (51.7-72.5)98NR21.1 (10.9-31.3)92/23/236
RFA2562.1 (51.7-72.5)9821.1 (10.9-31.3)36
Cillo et al[41], 2014Pros/RetroItaly2004-2010MWA4264 (47–81)8350NR24
RFA10063 (34–81)83NR24
Ciruolo et al[42], 2020RetroItaly2013-2019MWANR6471.778NRNRNR
RFA172
Ding et al[43], 2013RetroChina2006-2010MWA11359.06 (30–86)75.213125.5 (8–50)75/38/018.3 (3–51.4)
RFA8558.64 (40–77)809823.8 (10–48)49/36/027.7 (4–60)
Du et al[44], 2020RetroChina2014-2016MWA21856.3 (46.3-66.3)8013624 (13-35)107/8/028 (15-51)
RFA23457.5 (48-67)76.513726 (15-37)105/10/0
Gaia et al[45], 2021RetroItaly2013-2019MWA8167 (57–73)76.57729 (20–35)71/10/020.4 (10.8-38.4)
RFA17063 (56–72)69.416920 (15–25)148/22/034.8 (19.2–51.6)
Ghweil et al[46], 2019ProsEgypt2019MWA25NRNRNRNRNRNR
RFA30
Iida et al[47], 2013RetroJapan2001-2012MWA4070.1 (63.5-76.7)NRNR20 (11-29)NRNR
RFA1873.5 (69.5-77.5)21 (16-26)
Ding et al[48], 2013RetroChina2002-2011MWA55658.4 (48.1-68.7)74.8109023 (12-34)466/167/22(6-75)
RFA32358 (47.8-68.3)79.856222.8 (11.7-33.9)248/106/22(6-75)
Kuang et al[49], 2011ProsChina1997-2008MWA1955 (27-74)94NRNR77/4 /045 (24-155)
RFA31
Kumbar et al[50], 2018RetroIndia2018MWA25(40-85)9233NR13/8/415
RFA25883517/8/0
Lee et al[51], 2017RetroHong Kong2003-2011MWA2662.5 (49-79)73.12837.5 (20-60)23/3/047.5 (11.3-62.5)
RFA4758 (43-77)85.15231 (20-60)42/5/052.9 (3.6-121.8)
Liu et al[52], 2018RetroChina2002-2017MWA12654 (45, 60)90.516222.5 (17, 29)NR36.8 (1-115)
RFA43656 (46, 65)89.748223.0 (18, 30)34.1 (1-171)
Loriaud et al[53], 2018RetroFrance & Switzerland2007-2015MWANR69 (61–75)92.54022.5 (10–47)40/0/028 (10-46)
RFA67 (58-74)85.812021.3 (10-46)111/9/0
Lu et al[54], 2005RetroChina1997-2002MWA4950.1 (24–74)89.89825 (9–72)22/27/025.1 (2.0–50.6)
RFA5354.5 (20–74)81.17226 (10–61)47/6/024.8 (2.0–51.0)
Mocan et al[55], 2017RetroRomania2010-2016MWANRNRNR22NRNR12 (5.6-18.4)
RFA7922.8 (7.8-37.4)
Nocerino et al[56], 2016RetroItaly2016MWA106NRNR13420.4 (11-37)NR12 (5.6-18.4)
RFA273520.1 (7-34)22.8 (7.8-37.4)
Ohmoto et al[57], 2008RetroJapan2002-2006MWA4964 (38–75)83.75617 (8–20)31/14/433.5 (9.8-57.2)
RFA3467 (44–78)73.53716 (7–20)20/11/325.9 (14.6-37.2)
Potretzke et al[58], 2016RetroUS2001-2013MWA9961 (44–82)81.813622 (20–23)NR24
RFA5562 (23–88)72.76924 (22–26)31
Sakaguchi et al[59], 2009ProsJapan2009MWA142NRNRNRNRNRNR
RFA249
Santambrogio et al[60], 2017RetroItaly2009-2015MWA6070 (61.7-78.3)72NR21.5 (16.2-26.8)60/0/031 (15–46)
RFA9469 (60-78)7319.2 (14.2-24.2)94/0/0
Sever et al[61], 2018RetroTurkey2012-2015MWA2063.6 (57.3-69.9)653728 (18-38)14/4/212 (1-40)
RFA2064.3 (55.3-73.3)703424 (13-35)11/4/5
Shum et al[62], 2016RetroHong Kong2014-2015MWA22NRNRNRNRNR19
RFA4418
Simo et al[63], 2011RetroUS2006-2008MWA1359.6 (49–72)541523.1 (14–39)12/7/37 (2.5–10.5)
RFA2258 (45–79)862725.3 (12–44)7/6/019 (1.5–31)
Suwa et al[64], 2021RetroJapan2014-2020MWA7274.9 (66.5-83.3)65.3NR17.7 (10.9-24.5)58/14/012
RFA7274.4 (65.2-83.6)68.1NR17.6 (11.3-23.9)61/11/037.8
Suwa et al[65], 2020RetroJapan2016-2019MWA4473.4 (65.7-81.1)685217.2 (12.3-22.1)12/3/29NR
RFA5573.4 (65.7-81.1)807017.7 (11.3-24.1)16/8/31
Vogl et al[66], 2015RetroEgypt2008-2010MWA2860 (45-68)82.13236 (9-50)NRNR
RFA2557 (40-64)763632 (8-45)
Xu et al[67], 2004RetroChina1997-2001MWA5453.4 (24–74)86.611225 (15-36)53/33/1127.4 (2–53)
RFA437826 (12-40)
Xu et al[68], 2017RetroChina2007-2012MWA30154.2 (43.2-65.2)78.1NR17 (14-20)278/23/053 (8–98)
RFA15954.0 (43-65)8317 (14-20)140/19/062 (6–102)
Yin et al[69], 2009RetroChina1997-2007MWA4953 (41-65)87.2NR39 (31-47)NR22 (2.2-93.5)
RFA59
Zhang et al[70], 2013RetroChina2006MWA7754 (26–76)70.2105NR77/0/024.5 (6–64)
RFA7854 (30–80)82.19378/0/026.3 (7–65.6)
Zhang et al[71], 2014ProsChina2014MWA45NRNR60NRNRNR
RFA5668
Table 2 Summary of the comparison of OS and local recurrence rates between microwave ablation versus radiofrequency ablation for intrahepatic hepatocellular lesions in both cohort studies and RCTs according to year of follow-up
Endpoint
Study design
No. of studies
OR
95%CI
P for significance
I2
P for heterogeneity
Overall survival – OR
1YProspective 13.000.33-27.480.331--
Retrospective 111.190.71-1.990.51300.72
RCT 41.950.71-5.340.19435.50.20
2Y Retrospective71.270.75-2.180.37736.60.15
RCT 11.840.54-6.280.333--
3Y Prospective 11.690.59-4.810.328--
Retrospective91.140.75-1.730.55458.10.01
RCT 20.980.62-1.540.92900.62
4YRetrospective50.770.46-1.290.32360.80.04
5Y Prospective21.490.31-7.220.62071.20.06
Retrospective50.860.62-1.190.35734.80.19
RCT 20.790.50-1.150.19700.76
UnspecifiedRetrospective41.541.15-2.050.00400.50
RCT 21.470.73-2.960.28200.50
Local recurrence rate – OR
1YRetrospective40.780.29-2.110.61962.80.04
RCT 31.090.39-3.050.87200.40
2Y Retrospective41.000.40-2.450.99276.20.06
RCT 21.020.23-4.580.97570.40.07
3YRetrospective20.800.11-5.970.82684.80.01
RCT 10.730.30-1.80.493--
4YRetrospective22.141.12-4.070.02100.86
5Y Prospective12.220.49-10.020.301--
RCT 10.520.30-0.910.023--
Unspecified Prospective30.600.25-1.390.23300.44
Retrospective200.670.51-0.870.00237.20.05
10.260.06-1.070.063--
Table 3 Summary of the comparison of median and mean overall survival rates between microwave ablation versus radiofrequency ablation for intrahepatic hepatocellular carcinoma lesions in both cohort studies and randomised controlled trials
YearMWA sample sizeRFA sample sizeMedian OS
P value
MWA
RFA

11135162396.2%95.4%0.31
265178990.7%88.0%0.10
31004148080.5%75.3%0.002
442146476.8%70.0%0.02
5764122167.3%69.5%0.30
Table 4 Summary of overall survival and local recurrence rate HRs
Endpoint
Study design
No. of studies
HR
95%CI
P for significance
I2
P for heterogeneity
Overall survival – HR
Univariate Retrospective 21.170.75-1.830.49717.50.27
MultivariateRetrospective 31.320.92-1.890.1300.80.36
Unspecified Prospective 11.450.96-2.190.078--
Retrospective 131.060.86-1.320.58058.60.004
RCT 41.340.97-1.860.07900.58
Local recurrence rate – HR
Univariate Retrospective 31.770.81-3.880.15163.90.06
MultivariateRetrospective 21.880.79-4.470.15156.10.13
Cox proportionalRetrospective 12.171.04-4.500.040--
Fine and grayRetrospective 12.070.95-4.260.070--
UnspecifiedRetrospective 12.000.50-8.000.326--
Table 5 Microwave ablation versus radiofrequency ablation for hepatocellular lesions: Meta-analysis of adverse events
Adverse event
No. of studies
OR
95%CI
P for significance
I2
P for heterogeneity
Liver-related morbidity111.510.64-3.550.34200.91
Postprocedural infections191.30.85-1.970.22200.83
Postprocedural bleeding102.360.92-6.070.07500.97
Bile duct injury51.880.57-6.230.29900.99
Respiratory events 141.991.07-3.710.0300.87
Local events41.620.49-5.360.42600.57